ReviewCanadian journal of gastroenterology & hepatology2021
Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?
Review in Canadian journal of gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 53 citations in OpenAlex.
- Liver Fibrosis Screening in Childhood Acute Lymphoblastic Leukemia Survivors by Transient Elastography: A Case-Control Study.Indian pediatrics · 2026Article
- Multiparametric Abdominal Ultrasound as a Source of Imaging Biomarkers in Predictive and Personalized Medicine: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Non-invasive imaging diagnostic techniques in metabolic dysfunction-associated steatotic liver disease: a roadmap for clinicians.Hormones (Athens, Greece) · 2026Review
- Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States.Obesity (Silver Spring, Md.) · 2026Article
- Discordance Between Conventional Ultrasound and Transient Elastography in Hepatic Steatosis Assessment: Clinical Factors Associated with Discrepant Findings.Diagnostics (Basel, Switzerland) · 2026Article
- Attention-based graph neural network framework for non-invasive CAP score prediction in fatty liver disease via body modeling.Physical and engineering sciences in medicine · 2026Article
- Adipokine profiles reflect metabolic dysfunction but not fibrosis in patients with primary biliary cholangitis.World journal of hepatology · 2026Article
- Development and progression of hepatic steatosis during long-term glucocorticoid therapy in autoimmune hepatitis: multimodal evidence from biopsy, CAP, and ultrasound.Frontiers in medicine · 2026Article
- Gut Microbiota-Metabolite Alterations Associated with Early Metabolic Dysfunction and Hepatic Steatosis in Adolescents.Computational and structural biotechnology journal · 2026Article
- Increased transient elastography-derived liver stiffness in fibrotic interstitial lung disease compared with healthy controls and its association with high-resolution computed tomography extent: a cross-sectional observational study.Rheumatology international · 2025Observational
- Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today's World.Current hepatology reports · 2025Article
- A COM-B-guided lifestyle intervention reduces metabolic syndrome in overweight and obese adolescents: a multiphase study in Vietnam.Scientific reports · 2025Article
- Clinically significant portal hypertension assessed by spleen stiffness measurement and its associated outcomes among people living with HIV/AIDS.Scientific reports · 2025Article
- The importance of patient engagement in the multimodal treatment of MASLD.Communications medicine · 2025Review
- Accuracy of Controlled Attenuation Parameter for Liver Steatosis in High-Risk Patients for MASLD Using MRI-Proton Density Fat Fraction as Reference Standard.Digestive diseases and sciences · 2025Article
- Evaluating Pediatric NAFLD with Controlled Attenuation Parameter: A Comprehensive Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Nine anthropometric indices predict hepatic steatosis and assess liver health in adolescents: a population-based study.Frontiers in pediatrics · 2025Article
- Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial.Diseases (Basel, Switzerland) · 2024Article
- Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria.Journal of diabetes · 2024Article
- Body composition differences in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver diseases (CLDs) are a public health problem, even if frequently they are underdiagnosed. Hepatic steatosis (HS), encountered not only in nonalcoholic fatty liver disease (NAFLD) but also in chronic viral hepatitis, alcoholic liver disease, etc., plays an important role in fibrosis progression, regardless of CLD etiology; thus, detection and quantification of HS are imperative. Controlled attenuation parameter (CAP) feature, implemented in the FibroScan® device, measures the attenuation of the US beam as it passes through the liver. It is a noninvasive technique, feasible and well accepted by patients, with lower costs than other diagnostic techniques, with acceptable accuracy for HS quantification. Multiple studies have been published regarding CAP performance to quantify steatosis, but due to the heterogeneity of CLD etiologies, of steatosis prevalence, etc., it had widely variable calculated cut-off values, which in turn limited the day-to-day utility of CAP measurements in clinical practice. This paper reviews published studies trying to suggest cut-off values usable in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.